Esophageal squamous cell carcinoma (ESCC) is a severe health threat, being a predominant subtype of esophageal cancer and contributing significantly to cancer-related mortality globally.

More information: Bo Tian et al, Dysregulated inclusion of BOLA3 exon 3 promoted by HNRNPC accelerates the progression of esophageal squamous cell carcinoma, Frontiers of Medicine (2024). DOI: 10. ...

Esophageal squamous cell carcinoma (ESCC) accounts for around 90% of esophageal cancers, especially in East Asia. New findings indicate that periostin, or POSTN, promotes ESCC progression by ...

The safety and short-term efficacy of neoadjuvant chemotherapy in elderly patients with resectable locally advanced esophageal squamous cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ...

The most common types of esophageal cancer are squamous cell carcinoma and adenocarcinoma. The American Cancer Society’s estimates about 16,940 new esophageal cancer cases diagnosed (13,360 in men and ...

Impact of time to surgery on outcomes in patients with advanced esophageal squamous cell carcinoma following neoadjuvant therapy: An exploratory analysis of phase III trial JCOG1109. This is an ASCO ...

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an improvement in response rates.

rates compared with neoadjuvant chemotherapy plus sintilimab in patients with locally advanced esophageal squamous cell carcinoma (ESCC), preliminary results from a randomized phase III trial in ...

A novel treatment approach combining neoadjuvant immunotherapy with chemoradiation showed promising results in patients with locally advanced esophageal squamous cell carcinoma (ESCC), according ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...